Search Results
Your search for William J. Gradishar, MD, FASCO, FACP matches 8 pages
Showing 1 - 8NCCN Honors Oncology Leaders Promoting Progress in Cancer Care
The National Comprehensive Cancer Network® (NCCN®) recently announced the recipients of 2022 awards for both internal and external champions advancing NCCN’s mission and helping all people with cancer to live better lives. The annual awards include the Rodger Winn Award for expert judgment and...
NCCN Clinical Practice Guidelines in Oncology: 2022 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 27th Annual Conference, which was again...
Anthracycline Plus Taxane Reduces Risk of Breast Cancer Recurrence at 10 Years
In a large patient-level meta-analysis of 16 trials, presented at the 2021 San Antonio Breast Cancer Symposium (SABCS),1 the combination of an anthracycline plus a taxane achieved a substantial 15% reduction in breast cancer recurrence at 10 years vs taxane chemotherapy alone, representing an...
PI3K Pathway Activation May Underlie Tamoxifen-Associated Uterine Cancer
Even though it is infrequent, uterine cancer can develop in patients treated with tamoxifen. A study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) suggests that the mechanism by which uterine cancers develop is tamoxifen-induced PI3K pathway activation.1 Patients treated with...
NCCN Clinical Practice Guidelines in Oncology: 2021 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 26th Annual Conference, which was held virtually...
NCCN Clinical Practice Guidelines in Oncology: 2019 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®), covering eight tumor types. NCCN Guidelines are now published for more than 70 tumor types and topics. Some of the key updates for 2019 were presented...
Treatment of Triple-Negative Breast Cancer With BRCA1/2 Mutations: More to Learn From Ongoing Trials
The treatment of triple-negative breast cancer remains a clinical challenge with no single validated target, though numerous pathways are druggable and are being investigated. In the subset of BRCA-mutated triple-negative breast cancer, the approval of the first poly (ADP-ribose) polymerase (PARP)...
ASCO Guideline on Endocrine Therapy for Metastatic Breast Cancer: Reaffirming Principles for Making Treatment Decisions
The role of endocrine therapy for hormone receptor–positive metastatic breast cancer is well established, and clinicians are strongly encouraged to consider one of several therapeutic options for the majority of patients who present with metastatic disease. The recent ASCO guideline on this topic, ...
